SS-31: Dosage & Administration

SS-31 (elamipretide) dosing in research:

Protocol	Dose	Frequency	Duration
Standard research	5–50 mg	Once daily	4–12 weeks
Clinical trials (Barth syndrome)	40 mg	Once daily SC	Ongoing

SS-31 concentrates in the inner mitochondrial membrane within minutes of administration, where it interacts with cardiolipin — a phospholipid critical for electron transport chain function. The rapid mitochondrial targeting allows for once-daily dosing despite the peptide's relatively short plasma half-life.

SS-31 comes in lyophilized form requiring reconstitution:

• Reconstitute with bacteriostatic water following standard procedures
• The solution should be clear after reconstitution
• Administer subcutaneously — abdomen or thigh are standard injection sites

Use the peptide calculator for reconstitution volumes. See the reconstitution guide for step-by-step instructions.

SS-31 timing considerations:

• Time of day: No strict timing requirement. Morning administration is common
• Fasting: Not required — SS-31's mitochondrial targeting is independent of metabolic state
• Cycle length: Research protocols range from 4 to 12 weeks. Clinical trials for Barth syndrome use ongoing daily administration
• Onset: Mitochondrial uptake occurs within minutes, but functional improvements in mitochondrial efficiency develop over weeks

Standard peptide storage:

• Lyophilized: -20°C long-term, 2–8°C for months
• Reconstituted: Refrigerate at 2–8°C, use within 28 days

See the peptide storage guide.